ClinicalTrials.gg

Program

VH3810109

A development code.

In GlaxoSmithKline's pipeline, HIV broadly neutralizing antibody. Its studies are mostly in HIV Infections, led by GlaxoSmithKline.

Furthest: phase 2, since Aug 9, 20233 company-led studies, 2 open or runningNext primary completion: Jan 22, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline32 open or runningphase 2since Aug 9, 2023Feb 16, 2022Jan 22, 2027phase 1 · NCT07053384
  • Named in GlaxoSmithKline’s own pipeline as VH3810109, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 16, 2022First study: phase 1 study in HIV InfectionsFirst studyNCT05291520 · 24 enrolled · United States
  2. Aug 9, 2023Phase 2 study in HIV InfectionsNCT05996471 · 185 enrolled · United States, Puerto Rico
  3. Jun 26, 2025Phase 1 study in HIV InfectionsNCT07053384 · 107 enrolled · United States, Belgium, Denmark and more

Ahead

  1. Jan 22, 2027Primary completion: phase 1 study in HIV InfectionsNCT07053384

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“HIV broadly neutralizing antibody”the company's pipeline, read by Claude · source
“This study investigates the use of VH3810109 with or without FTR to reduce the size and activity of the HIV viral reservoir in two sub-populations of people living with HIV: treatment-naïve adults (Population 1) and treatment-experienced adults currently taking a standard of care (SOC) integrase …”study summary, read by Claude · the study

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07053384HIV Infections · United States, Belgium, Denmark and more1Active, not recruitingJan 22, 2027107
NCT05996471HIV Infections · United States, Puerto Rico2Active, not recruitingMay 27, 2026185
NCT05291520HIV Infections · United States1CompletedApr 10, 202324

How it is read

Names in the registry

  • “VH3810109”, 3 entries

Codes read as this program: VH3810109.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
VH3810109 (GlaxoSmithKline): development program | ClinicalTrials.gg